David Emerson Jorden - 01 Jan 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Role: CEO/CFO, Director
Signature: /s/ David Jorden
Issuer symbol: AURX
Transactions as of: 01 Jan 2026
Net transactions value: -$0.57
Form type: 4
Filing time: 05 Jan 2026, 19:25:34 UTC
Previous filing: 03 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JORDEN DAVID EMERSON	CEO/CFO, Director	C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON	/s/ David Jorden	05 Jan 2026	0001313516

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AURX	Common Stock	Options Exercise	$50,000	+125,000	+6.4%	$0.4000	2,071,755	01 Jan 2026	Direct
transaction	AURX	Common Stock	Tax liability	$50,001	-25,381	-1.2%	$1.97	2,046,374	01 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AURX	Option to purchase common stock	Options Exercise	$0	-125,000	-100%	$0.000000	0	31 Dec 2018	Common Stock	125,000	$0.4000	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a net exercise of outstanding stock options. The reporting person received 99,619 shares of common stock on the net exercise of option to purchase 125,000 shares of common stock. The issuer withheld 25,381 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.97.